Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in Primary CNS Lymphoma
NCT02934204Phase 2Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Feb 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in primary central nervous system lymphoma (PCNSL), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Event Free Survival at 3 years. Status: unknown.
02
Drugs
temozolomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT02934204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934204.